In order to study whether IL-17A confers a survival advantage to the Mo-DCs of LCH patients thanks to the BCL2A1 induction, we then cultured these Mo-DCs either in medium alone or in medium containing isotype control or neutralizing anti-IL-17A antibodies. The gene discussed is BCL2A1; the disease is Langerhans cell histiocytosis.